Sinopharm reports weaker profit. Sinopharm stock sits 34.06 percent below its high

Sinopharm reported lower first-half profit and revenue on September 22, 2026, while Sinopharm stock stood 34.06 percent below its 52-week high of HKD 22.34. FilingReader reported the six-month figures from the period ended June 30, 2026.

Profit pressure remains visible

Operating income fell 1.13 percent year over year to RMB 282.8 billion in the first half of 2026. Net profit declined 2.95 percent to RMB 5.18 billion, while net profit attributable to the parent company fell 1.79 percent to RMB 3.40 billion.

Basic earnings per share decreased 1.80 percent to RMB 1.09 for the same period. The overall expense ratio improved by 0.27 percentage points to 4.11 percent, showing that cost control partly offset weaker distribution activity.

Retail pharmacy offsets distribution decline

Pharmaceutical distribution revenue fell 1.39 percent to RMB 215.50 billion in the first half of 2026, while medical device distribution revenue declined 0.35 percent to RMB 56.85 billion. The contrast came from retail pharmacy, where revenue increased 8.58 percent to RMB 18.64 billion.

MarketScreener describes Sinopharm as a pharmaceutical distribution, medical device and retail pharmacy group with four operating segments. Its profile also lists 15 analysts in the consensus and an average target price of CNY 18.06, compared with a cited last close of CNY 12.85.

Stock remains below its yearly high

On the Hong Kong Exchange, Sinopharm was last at HKD 14.73 on October 2, 2026 at 4:08 p.m. HKT, down 0.87 percent versus the prior close of HKD 14.86. The 52-week range was HKD 14.58 to HKD 22.34, placing the quote 34.06 percent below the high and 1.03 percent above the low.